PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.00
D/E less than half of TRVN's 0.02. Charlie Munger would verify if this conservative approach provides competitive advantages.
3.47
Similar net debt to TRVN's 3.68. Guy Spier would examine if industry leverage norms make sense for both companies.
-4767.88
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
8.59
Similar current ratio to TRVN's 8.14. Guy Spier would investigate if industry liquidity norms make sense for both companies.
No Data
No Data available this quarter, please select a different quarter.